Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELVN Enliven Treateutics

Pre-Mkt 10-13 07:29:43 EDT

40.84

-0.14

-0.34%

盘前41.95

+1.11+2.72%

07:22 EDT

High41.41	Low40.50	Vol579.82K
Open40.67	D1 Closing40.98	Amplitude2.22%
Mkt Cap2.99B	Tradable Cap2.52B	Total Shares73.27M
T/O23.67M	T/O Rate0.94%	Tradable Shares61.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":40.84,"timestamp":1791835200000,"preClose":40.98,"halted":0,"volume":579824,"hourTrading":{"tag":"盘前","latestPrice":41.95,"preClose":40.84,"latestTime":"07:22 EDT","volume":3,"amount":124.56999,"timestamp":1791890558061,"change":1.11,"changeRate":0.027179,"amplitude":0.03379},"delay":0,"changeRate":-0.003416300634455673,"floatShares":61725902,"shares":73270761,"eps":-1.67535,"marketStatus":"Pre-Mkt","change":-0.14,"latestTime":"10-13 07:29:43 EDT","open":40.67,"high":41.41,"low":40.5,"amount":23673825.43792,"amplitude":0.022206,"askPrice":45.04,"askSize":100,"bidPrice":40.5,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.67535,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791898200000},"marketStatusCode":1,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":40.84,"preHourTrading":{"tag":"盘前","latestPrice":41.95,"preClose":40.84,"latestTime":"07:22 EDT","volume":3,"amount":124.56999,"timestamp":1791890558061,"change":1.11,"changeRate":0.027179,"amplitude":0.03379},"postHourTrading":{"tag":"盘后","latestPrice":40.84,"preClose":40.84,"latestTime":"19:30 EDT","volume":6357,"amount":259619.88,"timestamp":1791847803358,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.39876784600131177,"impliedVol":0.6571,"impliedVolPercentile":0.528},"requestUrl":"/m/hq/s/ELVN/tweets","defaultTab":"tweets","newsList":[{"id":"2674819341","title":"Enliven Therapeutics (ELVN), Why Is Fresh Attention Building Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674819341","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674819341?lang=en_us&edition=fundamental","pubTime":"2026-10-11 11:38","pubTimestamp":1791689937,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) is back in focus after the company aligned with the U.S. Food and Drug Administration on the final design of ENABLE-2, its planned pivotal Phase 3 trial for relcobatinib in chronic myeloid leukemia.\nEnliven Therapeutics has seen sharp swings around these clinical updates, with the share price down 24.56% over the past 30 days but still showing a 163.71% year to date share price return and a 234.53% three year total shareholder return. This points to strong long...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-why-is-fresh-attention-building-no","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-why-is-fresh-attention-building-no","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ELVN","LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673730780","title":"TD Cowen Remains a Buy on Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673730780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673730780?lang=en_us&edition=fundamental","pubTime":"2026-10-08 17:55","pubTimestamp":1791453341,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics. The company’s shares closed yesterday at...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-enliven-therapeutics-elvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-enliven-therapeutics-elvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","COWN","BK4007","BK4539","BK4127","ELVN","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709943","title":"Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709943","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709943?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:01","pubTimestamp":1791363707,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics  is on track to start its phase 3 trial of relcobatinib in patients with previously treated chronic myeloid leukemia before the end of 2026, the company said Wednesday.The move comes after the company aligned with the US Food and Drug Administration on the trial's final design.The trial is designed to directly compare relcobatinib with second-generation tyrosine kinase inhibitors and is expected to enroll 450 adults with chronic myeloid leukemia.The primary endpoint is major molecular response at week 24, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","ELVN","LABU","BK4007","LENZ","BK4585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673686063","title":"Enliven Therapeutics Announces FDA Alignment on Enable-2 Phase 3 Trial Design for Relcobatinib (Elvn-001) in Previously Treated Chronic Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673686063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673686063?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:05","pubTimestamp":1791317101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA3WT9FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673063500","title":"Enliven Therapeutics - on Track to Initiate Enable-2 Phase 3 Trial Before Year-End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673063500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673063500?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:05","pubTimestamp":1791317101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA3WT9FW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673264084","title":"Enliven Therapeutics Director Garland J. Scott Disposes of $606,719 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673264084","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673264084?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:57","pubTimestamp":1791233876,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics director Garland J. Scott disposes of $606,719 in common sharesDirector Garland J. Scott exercised stock options for 13,000 Enliven Therapeutics common shares on Oct. 1, 2026 at U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL1Y6l5p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics Director Garland J. Scott Disposes of $606,719 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672671391","title":"Enliven initiated with an Overweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2672671391","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672671391?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:15","pubTimestamp":1790932508,"startTime":"0","endTime":"0","summary":"Morgan Stanley initiated coverage of Enliven (ELVN) with an Overweight rating and $70 price target Enliven is a clinical-stage precision oncology c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-an-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-an-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANC","BK4007","CNCR","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672673191","title":"Enliven Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $75","url":"https://stock-news.laohu8.com/highlight/detail?id=2672673191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672673191?lang=en_us&edition=fundamental","pubTime":"2026-10-01 12:21","pubTimestamp":1790828492,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N08I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669219308","title":"Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 250,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2669219308","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669219308?lang=en_us&edition=fundamental","pubTime":"2026-09-22 05:22","pubTimestamp":1790025762,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics CMO Helen Louise Collins disposes of USD 250,000 in common sharesEnliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares at $2.48 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL37mFSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 250,000 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664780976","title":"Enliven Therapeutics Management to Attend Morgan Stanley Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664780976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664780976?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:05","pubTimestamp":1788465935,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics management to attend Morgan Stanley global healthcare conference fireside chatEnliven Therapeutics management will attend investor meetings at the Wells Fargo 21st Annual Healthca","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL3jDRcC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851558","title":"Enliven Therapeutics to Present Phase 1 Enable Trial Data for ELVN-001 in CP-CML at SOHO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851558","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851558?lang=en_us&edition=fundamental","pubTime":"2026-09-01 06:05","pubTimestamp":1788213922,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics to present Phase 1 ENABLE trial data for ELVN-001 in CP-CML at SOHO 2026Enliven Therapeutics scheduled an encore data presentation from its ENABLE Phase 1 trial of ELVN-001 at SOH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL9DBd91:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885902","title":"Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (Soho) 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664885902?lang=en_us&edition=fundamental","pubTime":"2026-09-01 06:05","pubTimestamp":1788213900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA9WBWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661784220","title":"Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661784220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661784220?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:20","pubTimestamp":1787566808,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enliven Therapeutics (ELVN), Argenx Se (ARGX) and Aq...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FMED","IE0034235188.USD","IE0009355771.USD","BK4007","ARGX","IE00BJT1NW94.SGD","IBB","LU0823416689.USD","IE00BJJMRZ35.SGD","BK4505","LU0109394709.USD","BK4139","BK4585","LU0320765992.SGD","ELVN","LU1983260115.SGD","LU0889565916.HKD","IE00B2B36J28.USD","LU2324357040.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4588","TBXU","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660047333","title":"Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2660047333","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660047333?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:17","pubTimestamp":1787170628,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics CMO Helen Louise Collins reports disposal of 5,000 common shares worth $293,612.17Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDLbx8wnX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469285","title":"Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469285?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:34","pubTimestamp":1787049270,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F055:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469656","title":"Enliven initiated with an Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469656?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:15","pubTimestamp":1787048149,"startTime":"0","endTime":"0","summary":"William Blair initiated coverage of Enliven (ELVN) with an Outperform rating. The company is advancing ELVN-001, a “highly selective and efficaciou...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660346624","title":"Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2660346624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660346624?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:05","pubTimestamp":1787047516,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660488079","title":"U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2660488079","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660488079?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:16","pubTimestamp":1786954612,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell TechnologiesAug 17 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4N44E0FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXE","DAVE","EAT","EOG","PXE","TGT","BMRN","BYND","EQT","ESS","CHPS","DVN","AVBP","APP","DCH","CVX","ABBV","APA","DNTH","AMTM","CPT","XLE","ELS","HON","CHRD","FHLC","CLYM","ALAB","AVB","COP","URAN","RDVY","AHR","AMAT","TDV","FANG","CCAP","DELL","DUK","BCSF","AEP","BILT","AMLX","DLTR","ELVN","CBRE","CRWD","TINY","RSPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165205","title":"Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165205","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165205?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:36","pubTimestamp":1786635368,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Dara Azar reiterated a Buy rating on Enliven Therapeutics today and set a price target of $82.00. According to TipRanks, Az...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/enliven-therapeutics-elvn-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/enliven-therapeutics-elvn-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4127","LENZ","ELVN","BK4539","BK4139","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657776664","title":"Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657776664","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657776664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:18","pubTimestamp":1786061923,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics director Mika K. Derynck sells USD 9.56 million in common sharesEnliven Therapeutics director Mika K. Derynck sold 158,795 shares on Aug. 4 at a weighted average price of $60.21.T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL8myvFk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.enliventherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1018},{"period":"1month","weight":-0.2482},{"period":"3month","weight":-0.2105},{"period":"6month","weight":-0.0708},{"period":"1year","weight":0.9616},{"period":"ytd","weight":1.6519}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.026887},{"month":2,"riseRate":0.666667,"avgChangeRate":0.05311},{"month":3,"riseRate":0.666667,"avgChangeRate":0.048411},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.063791},{"month":5,"riseRate":0.285714,"avgChangeRate":0.136586},{"month":6,"riseRate":0.857143,"avgChangeRate":0.068871},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.079074},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.023395},{"month":9,"riseRate":0.428571,"avgChangeRate":0.071815},{"month":10,"riseRate":0.428571,"avgChangeRate":0.09136},{"month":11,"riseRate":0.166667,"avgChangeRate":0.036396},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.10748}],"exchange":"NASDAQ","name":"Enliven Treateutics","nameEN":"Enliven Treateutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Enliven Treateutics,ELVN,Enliven Treateutics股票,Enliven Treateutics股票老虎,Enliven Treateutics股票老虎国际,Enliven Treateutics行情,Enliven Treateutics股票行情,Enliven Treateutics股价,Enliven Treateutics股市,Enliven Treateutics股票价格,Enliven Treateutics股票交易,Enliven Treateutics股票购买,Enliven Treateutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction